These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15904514)

  • 21. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
    Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Typhoid fever vaccination strategies.
    Date KA; Bentsi-Enchill A; Marks F; Fox K
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C55-61. PubMed ID: 25902360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
    Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
    BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan.
    Khan MI; Pach A; Khan GM; Bajracharya D; Sahastrabuddhe S; Bhutta W; Tahir R; Soofi S; Thapa CB; Joshi N; Puri MK; Shrestha P; Upreti SR; Clemens JD; Bhutta Z; Ochiai RL
    Vaccine; 2015 Jun; 33 Suppl 3():C62-7. PubMed ID: 25937612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
    van Damme P; Kafeja F; Anemona A; Basile V; Hilbert AK; De Coster I; Rondini S; Micoli F; Qasim Khan RM; Marchetti E; Di Cioccio V; Saul A; Martin LB; Podda A
    PLoS One; 2011; 6(9):e25398. PubMed ID: 21980445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines.
    Keitel WA; Bond NL; Zahradnik JM; Cramton TA; Robbins JB
    Vaccine; 1994; 12(3):195-9. PubMed ID: 8165850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up.
    Acosta CJ; Hong-Hui Y; Ning W; Qion G; Qun D; Xiaolei M; Baode Z; Liu W; Danovaro-Holliday MC; Ochiai RL; Wang XY; Kim DR; Zhi-Yi X; Bai-Qing D; Galindo CM; Clemens JD
    Vaccine; 2005 Dec; 23(48-49):5618-23. PubMed ID: 16098635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of a targeted typhoid vaccination campaign following cyclone Tomas, Republic of Fiji, 2010.
    Scobie HM; Nilles E; Kama M; Kool JL; Mintz E; Wannemuehler KA; Hyde TB; Dawainavesi A; Singh S; Korovou S; Jenkins K; Date K
    Am J Trop Med Hyg; 2014 Jun; 90(6):1031-8. PubMed ID: 24710618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination of active component US military personnel against Salmonella Typhi.
    Porter CK; Sorrell T; Mitra I; Riddle MS
    Vaccine; 2017 Mar; 35(14):1742-1748. PubMed ID: 28268075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design.
    Acosta CJ; Galindo CM; Ali M; Elyazeed RA; Ochiai RL; Danovaro-Holliday MC; Page AL; Thiem VD; Jin Y; Park JK; Lee H; Puri MK; Ivanoff B; Agtini MD; Soeharno R; Simanjuntak CH; Punjabi NH; Canh DG; Sur D; Nizami Q; Manna B; Bai-qing D; Anh DD; Honghui Y; Bhattacharya SK; Bhutta Z; Trach DD; Xu ZY; Pang T; Donner A; Clemens JD
    Trop Med Int Health; 2005 Dec; 10(12):1219-28. PubMed ID: 16359401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.
    Yang HH; Kilgore PE; Yang LH; Park JK; Pan YF; Kim Y; Lee YJ; Xu ZY; Clemens JD
    J Infect Dis; 2001 Jun; 183(12):1775-80. PubMed ID: 11372030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.
    Mirza NB; Wamola IA; Estambale BA; Mbithi E; Poillet M
    East Afr Med J; 1995 Mar; 72(3):162-4. PubMed ID: 7796767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Typhoid vaccines.
    Aggarwal A; Dutta AK
    Indian J Pediatr; 2001 Aug; 68(8):733-6. PubMed ID: 11563251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
    Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
    PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity.
    Beran J; Beutels M; Levie K; Van Damme P; Dieussaert I; Gillet M; Van Hoecke C; Tornieporth N
    J Travel Med; 2000; 7(5):246-52. PubMed ID: 11231208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity.
    Proell S; Maiwald H; Nothdurft HD; Saenger R; Vollmar J; De Clercq N; von Sonnenburg F
    J Travel Med; 2002; 9(3):122-6. PubMed ID: 12088576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam.
    Kaljee LM; Pham V; Son ND; Hoa NT; Thiem VD; Canh DG; Thoa le TK; Ali M; Ochiai RL; Danovaro-Holliday MC; Acosta CJ; Stanton B; Clemens J
    Trop Med Int Health; 2007 Jan; 12(1):25-36. PubMed ID: 17207145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.
    Azze RF; Rodríguez JC; Iniesta MG; Marchena XR; Alfonso VM; Padrón FT
    Vaccine; 2003 Jun; 21(21-22):2758-60. PubMed ID: 12798615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
    Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.